Royce & Associates LP Silverback Therapeutics, Inc. Transaction History

Royce & Associates LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	SELL	N/A	-386,497 Reduced 60.13%	256,269 $0
Q1 2025 May 06, 2025	SELL	N/A	-286,847 Reduced 30.86%	642,766 $0
Q4 2024 Feb 10, 2025	BUY	N/A	238,158 Added 34.44%	929,613 $0
Q3 2024 Nov 06, 2024	BUY	N/A	45,755 Added 7.09%	691,455 $0
Q2 2024 Aug 13, 2024	BUY	N/A	87,000 Added 15.57%	645,700 $0

Q1 2024 May 13, 2024	BUY	N/A	85,000 Added 17.94%	558,700 $0
Q4 2023 Feb 12, 2024	BUY	N/A	10,000 Added 2.16%	473,700 $0
Q2 2023 Aug 07, 2023	BUY	N/A	159,800 Added 52.58%	463,700 $0
Q1 2023 May 04, 2023	BUY	N/A	303,900 New	303,900 $1.98 Million

211

84.3M

1.21M

687K

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.